Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 918 people across three groups. One group (310 people) took fostamatinib 100 mg twice a day by mouth throughout the study. A second group (304 people) started on fostamatinib 100 mg twice a day, then switched to 150 mg once a day after four weeks. A third group (304 people) took a placebo (a dummy tablet with no active ingredient) for 24 weeks, then switched to fostamatinib 100 mg twice a day. The trial was measuring how well fostamatinib reduced signs of rheumatoid arthritis activity compared to placebo, and whether it slowed joint damage visible on X-rays, over 24 weeks. The reported data shows that at the 24-week mark, 49% of people in the first fostamatinib group and 44.4% in the second fostamatinib group met the trial's main measure of improvement in joint symptoms — compared with 34.2% in the placebo group. For joint damage visible on X-rays (scored on a scale of 0 to 448, where higher numbers mean more damage), the reported average change from the start of the trial was 0.45 points in the first fostamatinib group and 1.29 points in the second, compared with 0.13 points in the placebo group. For secondary measures, the reported data shows that after just one week, about 18.2% of combined fostamatinib participants met the improvement threshold, versus 4.9% in the placebo group. At 24 weeks, the proportions meeting higher improvement thresholds (a 50% or 70% improvement in symptoms) were also reported as higher in the fostamatinib groups than in the placebo group. The reported data also shows an overall average symptom improvement score at 24 weeks of 26.1% for the first fostamatinib group and 20.1% for the second, compared with 12.9% for the placebo group. These numbers describe what was measured and recorded in this trial; they do not account for individual variation between patients, and not all participants completed the study. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 29669391) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Rheumatoid Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with rheumatoid arthritis (RA), and you were at least 16 years old when you were diagnosed
- You are currently taking the medication methotrexate
- You have 6 or more swollen joints AND 6 or more tender or painful joints, plus at least one of two specific blood test results showing signs of inflammation (confirm with trial site)
- You have at least one of the following: a past or current positive blood test for rheumatoid factor, signs of joint damage seen on an X-ray within the last 12 months, or a positive blood test for a specific antibody linked to RA (anti-CCP antibodies)
Who may not be able to join:
- You are currently pregnant or breastfeeding
- You have high blood pressure that is not well controlled
- You have liver disease or abnormal liver test results
- You have certain other inflammatory conditions, connective tissue diseases, or long-term pain conditions (other than RA) (confirm with trial site)
- You have a serious heart or blood vessel condition, either recent or ongoing
- You have a significant active or recent infection, including tuberculosis
- You have previously tried a type of medication called a TNF alpha antagonist or anakinra and it did not work for you, or you have previously been treated with certain other biological medicines
- You have severely reduced kidney function
- You have a low level of a type of white blood cell called neutrophils (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Neil MacKillop, MD PhD, AstraZeneca
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo.; Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.